Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Killer’ cells used to combat rare cancer

10.09.2002


Scientists from the University of Edinburgh are using immune cells harvested from blood donors to help fight an unusual cancer which can affect transplant patients. And their findings, published recently in The Lancet show that the therapy has proved effective in a number of cases. The treatment proved successful last year in saving the life of a four-year-old boy from Birmingham, who developed the cancer— post-transplant lympho-proliferative disease— following a liver and bowel transplant.



The technique, which involves boosting the patient’s own immune system to fight cancer without affecting the transplanted organ, can also be adapted to treat other virus infections, or AIDS patients who have developed lymphomas.

Clinical research scientist Dr Tanzina Haque explained: “The Epstein-Barr virus (EBV) is a common virus best known for causing glandular fever, and is carried by about 90% of the population, without a problem. When a patient receives an organ transplant, he or she is given immuno-suppressive drugs to stop the body rejecting the organ, but this also lowers their immunity to infections by removing the body’s ’killer’ cells, the cytotoxic T-lymphocytes. If a transplant patient’s immunity is compromised, EBV can infect cells called B-lymphocytes, causing them to grow in an uncontrolled way and become malignant. The resulting cancer can be fatal in up to 70% of cases.”


Dr Haque said that to reduce doses of immuno-suppressive drugs could cause organ transplant rejection, so the Edinburgh team, headed by Professor Dorothy Crawford and backed by funding from Cancer Research UK, devised a method of removing ‘killer’ cells from screened blood donations and tissue-type matching them to transplant patients. Should any patients develop lymphoma, they can be infused with matched cells from the bank containing more than 100 blood donations.

The technique, known as Cytotoxic T-Lymphocyte (CTL) Therapy, has shown to have no adverse side-effects for patients. Results published in The Lancet show of eight patients in the trial who were suitable for treatment, two died, five made a complete recovery, two did not respond and one showed a partial response. Two further patients died before their tumour response could be evaluated.

Dr Haque said this UK-wide multicentre clinical trial could not have been possible without the collaboration of the Scottish National Blood Transfusion Service, different transplant centers, and the many blood donors who helped by allowing their blood to be used for generating the T-cells.

Linda Menzies | alfa
Further information:
http://www.ed.ac.uk/news/

More articles from Health and Medicine:

nachricht Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Why we need erasable MRI scans

New technology could allow an MRI contrast agent to 'blink off,' helping doctors diagnose disease

Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

European particle-accelerator community publishes the first industry compendium

26.04.2018 | Physics and Astronomy

Multifunctional bacterial microswimmer able to deliver cargo and destroy itself

26.04.2018 | Life Sciences

Why we need erasable MRI scans

26.04.2018 | Medical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>